Navigation Links
Avanir Pharmaceuticals to Participate in Two Conferences in August
Date:8/5/2014

ALISO VIEJO, Calif., Aug. 5, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that company management will present an overview of the company at the following conferences in August.

  • Wedbush Life Sciences Conference
    • Presentation date: Tuesday August 12, 2014
    • Presentation time: 9:45 a.m. ET
  • Canaccord Genuity Annual Growth Conference
    • Presentation date: Wednesday, August 13, 2014
    • Presentation time: 3:00 p.m. ET

A live webcast and 30-day archive of these presentations will be available at http://ir.avanir.com.

About Avanir Pharmaceuticals, Inc.

Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. For more information about Avanir, please visit www.avanir.com.

AVANIR® is a trademark or registered trademark of Avanir Pharmaceuticals, Inc. in the United States and other countries.

©2014 Avanir Pharmaceuticals, Inc. All Rights Reserved.

Avanir Investor & Media Contact
Ian Clements, PhD
ir@avanir.com
+1 (949) 389-6700

Logo - http://photos.prnewswire.com/prnh/20130207/LA55901LOGO


'/>"/>
SOURCE Avanir Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Avanir Pharmaceuticals To Present at Three Conferences In May
2. Avanir Pharmaceuticals Announces Date Of Fiscal 2012 Second Quarter Financial Results And Conference Call
3. Avanir Pharmaceuticals to Present at Jefferies 2012 Global Healthcare Conference
4. Avanir Pharmaceuticals Announces Date Of Fiscal 2012 Third Quarter Financial Results And Conference Call
5. Avanir Pharmaceuticals To Present At Two Investor Conferences In August
6. Avanir Pharmaceuticals Announces Enrollment Of First Patient In Study Of AVP-923 For The Treatment Of Agitation In Patients With Alzheimers Disease
7. Avanir Pharmaceuticals Announces Publication Of PBA Burden Of Illness Study
8. Avanir Pharmaceuticals To Present At UBS Global Life Sciences Conference
9. Avanir Pharmaceuticals Achieves Commercial Milestones & Provides Clinical Updates
10. Avanir Pharmaceuticals To Present At 24th Annual Piper Jaffray Healthcare Conference
11. Avanir Pharmaceuticals Pre-Announces Preliminary Fiscal 2012 Fourth Quarter Results And Provides Clinical Study Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... 28, 2015 According to a ... (Breast, Lung, Prostate) Type (Protein & Genetic Biomarkers) Profiling ... Prognostic) & Geography - Global Forecast to 2020", published ... reach around 17,689.0 Million USD by 2020 at a ... to 2020. Browse 191 Tables and ...
(Date:8/28/2015)... 2015 Research and ... of the "12th Annual Report and Survey ... to their offering. The 2015 12th ... and Production is the most recent study of ... projected future capacity and production. The report contains ...
(Date:8/28/2015)... WARRENVILLE, Ill. , Aug. 28, 2015 /PRNewswire/ ... Patterson Companies, Inc. (Nasdaq: PDCO ), is ... the previously announced acquisition of Patterson Medical by ... Medical will retain its name for a transition ... distributor of rehabilitation and sports medicine products.  With ...
Breaking Medicine Technology:Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 2Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 3Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 4Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 512th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 3
... subset analyses of progression-free survival in,the SPARC ... in,relative risk of disease progression for patients ... as well as presence or absence of ... Pharmion,Corporation and GPC Biotech AG today announced ...
... Results in Improved Long-term [Five-years],Overall Survival for ... 2007 /PRNewswire-FirstCall/ -- FOLFOX4, an,Eloxatin(R)-based chemotherapy regimen, ... survival (OS) and,time to disease progression (TTP) ... in patients with metastatic (advanced) colorectal cancer.,Importantly, ...
Cached Medicine Technology:Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 2Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 3Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 4Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 5Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 6Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 7Eloxatin (oxaliplatin injection)-Based Chemotherapy Sets New,Treatment Benchmark in Patients With Metastatic Colorectal Cancer 2Eloxatin (oxaliplatin injection)-Based Chemotherapy Sets New,Treatment Benchmark in Patients With Metastatic Colorectal Cancer 3Eloxatin (oxaliplatin injection)-Based Chemotherapy Sets New,Treatment Benchmark in Patients With Metastatic Colorectal Cancer 4
(Date:8/29/2015)... ... 29, 2015 , ... "I have been a licensed physical ... specialize in manual therapy, and my invention will provide headache sufferers a solution ... muscle dysfunction throughout the body." , They developed THE RELIEVER to alleviates headaches, ...
(Date:8/29/2015)... ... August 29, 2015 , ... Next weekend is Labor Day weekend, ... officially ends on September 22nd this year). For IT security personnel, it should also ... which could prove far more costly than a simple headache. , Joe Caruso, founder ...
(Date:8/29/2015)... ... August 29, 2015 , ... Vascular Health Sciences ... sell Arterosil and Arterosil HP, and that all claims and counterclaims have been ... Sciences, LLC (VHS) in the United States District Court for the Southern District ...
(Date:8/28/2015)... ... , ... The Kentucky State Department of Workforce Investment Commissioner Beth Kuhn recently ... for, they are unable to pass the initial drug test and therefore unable to ... order to be able to hire long-term, skilled talent. (1) Will Wesch, Director of ...
(Date:8/28/2015)... ... August 28, 2015 , ... As reported by ... received FDA clearance for results that last for two years, the longest of ... for patients who are looking for a long-lasting, effective solution for their cellulite, according ...
Breaking Medicine News(10 mins):Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 3Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 4Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3
... the safety of a potential vaccine against mesothelioma, a ... which infuses uses a patient,s own dendritic cells (DC) ... induce a T-cell response against mesothelioma tumors. "[This] ... patients with mesothelioma," wrote Joachim G Aerts M.D., Ph.D., ...
... A new iPhone app designed ... gone on sale on the App Store , ... (PRWeb UK) March 3, 2010 -- The Quickka Calories PRO iPhone app is aimed at ... items that they eat., , ,In what is being called a perfect union between technology and ...
... ... ... ... ...
... ... , ... , , , ... HOUSTON , March ...
... University of Texas M. D. Anderson Cancer Center, researchers found ... bladder cancer, is a cost-effective method of detecting tumors. ... well as the number of false positives that may result ... The study was presented today in advance of the American ...
... University of Washington,s Dr. H. Hunter Handsfield, a long-time ... the nation,s highest honor in the STD field during ... STD Prevention Conference in Atlanta, March 8-11. Handsfield ... named for Dr. Thomas Parran, Jr., U.S. Surgeon General ...
Cached Medicine News:Health News:Possible vaccine for mesothelioma proven safe 2Health News:Barcode Joins the Battle of the Bulge in New iPhone App 2Health News:Osteotech to Present at the Canaccord Adams Musculoskeletal Conference 2Health News:Osteotech to Present at the Canaccord Adams Musculoskeletal Conference 3Health News:Omega Protein Comments on California Lawsuit Alleging Fish Oil Contaminants 2Health News:Costly tests may not help detect bladder cancer recurrence, M. D. Anderson study finds 2Health News:Dr. Hunter Handsfield wins prestigious Thomas Parran Award 2Health News:Dr. Hunter Handsfield wins prestigious Thomas Parran Award 3Health News:Dr. Hunter Handsfield wins prestigious Thomas Parran Award 4
The adult underbody blanket is conveniently positioned on the table before the patient arrives to the procedure suite....
The adult blanket provides full coverage for patients of all sizes. The generous size and versatility of these blankets include extra material for the shoulders and feet. The foot drape also reduces ...
The Bair Hugger outpatient blanket makes it easy to give your patients the benefit of prewarming and enhance patient comfort during outpatient procedures....
The full body blanket provides coverage to the entire patient....
Medicine Products: